+ 34 986 812 316

A. Linē lab. Cancer Biomarker and Immunotherapy.
Latvian Biomedical Research and Study Centre. Ratsupites str 1. LV-1067 Riga. Latvia

Extracellular vesicles, non-coding RNAs, oncology, biomarkers, carbonic anhydrases


cancer cell lines, primary cell cultures (breast, colorectal cancer, fibroblasts), 3-D cell cultures, patient samples


Isolation and characterisation of extracellular vesicles (EVs), analysis of RNA and DNA content in EVs, EV uptake, Ion Torrent PGM and Proton sequencers, microarrays, real-time PCR, siRNA, IHC, ICC, FACS, in vitro assays: MTT, proliferation, spheroid formation, invasion, migration, cell cycle.

Collaborations outside COST

Collaboration with oncology clinics for Cancer Biobanking (tissues, serum/plasma, follow-up info). Ongoing collaboration projects on cancer-derived EVs as biomarkers and drug targets for prostate, breast and gastrointestinal cancers. Collaboration with organic chemists on epigenetic drug testing.

Short description of ongoing research projects

Characterization of RNA and DNA content in EVs produced by breast, gastrointestinal and prostate cancers in order to assess to what extent the EV content reflect the genetic make-up of cancer cells and whether or not they can be exploited for detecting intratumoural heterogeneity of cancers. Another aspect of this study is to gain insight into cancer-derived EV tropism, biodistribution and functional effects on cancer-cancer and cancer-host crosstalk. Furthermore, we are interested in the impact of extracellular acidity on the functional phenotype of tumour infiltrating immune cells, CAIX as a drug target to abrogate immunosuppressive microenvironment and in inducing the formation of tertiary lymphoid structures (TLS) in the tumour microenvironment as a putative therapeutic strategy.

  1. Ivanova L, Zandberga E, Siliņa K, Kalniņa Z, Ābols A, Endzeliņš E, Vendina I, Romanchikova N, Hegmane A, Trapencieris P, Eglītis J, Linē A. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemotherapy and Pharmacology. 2015 Feb;75(2):235-46.
  2. Siliņa K, Rulle U, Kalniņa Z, Linē A. Manipulation of tumour infiltrating B cells and tertiary lymphoid structures - a novel anti-cancer treatment avenue? Cancer Immunology Immunotherapy. 2014 Jul;63(7):643-62
  3. Zayakin P, Ancāns G, Siliņa K, Meistere I, Kalniņa Z, Andrejeva D, Endzeliņš E, Ivanova L, Pismennaja A, Ruskule A, Doniņa S, Wex T, Malfertheiner P, Leja M, Linē A. Tumour-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2013 Jan 1;132(1):137-47.
  4. Zandberga E, Kozirovskis V, Ābols A, Andrejeva D, Purkalne G and Linē A. Cell-free microRNAs as diagnostic, prognostic and predictive biomarkers in lung cancer. Genes, Chromosomes & Cancer. 2013 Apr;52(4):356-69.
  5. K. Silina, P. Zayakin, Z. Kalnina, L. Ivanova, I. Meistere, E. Endzelins, A. Abols, A. Stengrevics, M. Leja, K. Ducena, V. Kozirovskis, A. Linē. Sperm associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother, 2011, Jan;34(1):28-44.
Other activities of potential interest to others

Alternate member of Committee for Advanced Therapies (CAT), European Medicines Agency (EMA) Editorial board member of Biomarkers in Cancer, Central European Journal of Biology, Journal of Circulating Biomarkers

Cost UE